Abstract
Aberrant Hedgehog (Hh) signaling plays an important role in the pathogenesis and maintenance of many cancers. The mechanisms by which this pathway contributes to tumor progression are only now being unraveled. There appear to be two distinct ways by which Hh signaling becomes constitutively activated in tumors: by over expression of the ligand itself, or by acquisition of mutations in Hh signaling components at or downstream of the Hh receptor. The goal of this review is to briefly present the key components of the Hh pathway, and then discuss the known inhibitors of this pathway. We will describe how each inhibitor was identified, what is known of its mechanism of action, and its potential as a therapeutic agent against tumors dependent on Hh signaling.
Keywords: hedgehog, cancer, cyclopamine, inhibitors, review
Current Cancer Therapy Reviews
Title: Inhibitors of the Hedgehog Signal Transduction Pathway
Volume: 1 Issue: 3
Author(s): David J. Robbins, John A. Goetz, Ziqiang Yuan and Melanie A. Stegman
Affiliation:
Keywords: hedgehog, cancer, cyclopamine, inhibitors, review
Abstract: Aberrant Hedgehog (Hh) signaling plays an important role in the pathogenesis and maintenance of many cancers. The mechanisms by which this pathway contributes to tumor progression are only now being unraveled. There appear to be two distinct ways by which Hh signaling becomes constitutively activated in tumors: by over expression of the ligand itself, or by acquisition of mutations in Hh signaling components at or downstream of the Hh receptor. The goal of this review is to briefly present the key components of the Hh pathway, and then discuss the known inhibitors of this pathway. We will describe how each inhibitor was identified, what is known of its mechanism of action, and its potential as a therapeutic agent against tumors dependent on Hh signaling.
Export Options
About this article
Cite this article as:
Robbins J. David, Goetz A. John, Yuan Ziqiang and Stegman A. Melanie, Inhibitors of the Hedgehog Signal Transduction Pathway, Current Cancer Therapy Reviews 2005; 1 (3) . https://dx.doi.org/10.2174/157339405774574243
DOI https://dx.doi.org/10.2174/157339405774574243 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Marine Food Protection in Testicular Damages Caused by Diabetes Mellitus
Current Diabetes Reviews Is the Modulation of Autophagy the Future in the Treatment of Neurodegenerative Diseases?
Current Topics in Medicinal Chemistry Recent Advances in the Membrane Receptor Initiated Vitamin D Signaling of Calcium and Phosphate Transport Across Intestinal and Kidney Epithelia
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) T-Cell Zeta Chain Expression, Phosphorylation and Degradation and their Role in T-Cell Signal Transduction and Immune Response Regulation in Health And Disease
Current Signal Transduction Therapy Role of NF-κB and NF-κB-regulated Gene Products in Chemoresistance and Radioresistance
Current Cancer Therapy Reviews Long-Term Safety from the Raltegravir Clinical Development Program
Current HIV Research To Seek Shelter from the Wnt in Osteoarthritis? Wnt-Signaling as a Target for Osteoarthritis Therapy
Current Drug Targets Chemotherapy and Molecular Therapy in Non-Melanoma Skin Cancer
Current Cancer Therapy Reviews Nanostructural Hybrid Sensitizers for Photodynamic Therapy
Current Pharmaceutical Design MRP1-dependent Collateral Sensitivity of Multidrug-resistant Cancer Cells: Identifying Selective Modulators Inducing Cellular Glutathione Depletion
Current Medicinal Chemistry Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Targeting the Hedgehog Pathway: The development of Cyclopamine and the Development of Anti-Cancer Drugs Targeting the Hedgehog Pathway
Mini-Reviews in Medicinal Chemistry Surface Markers of Cancer Stem Cells in Solid Tumors
Current Stem Cell Research & Therapy Stem Cell Differentiation Stage Factors and their Role in Triggering Symmetry Breaking Processes during Cancer Development: A Quantum Field Theory Model for Reprogramming Cancer Cells to Healthy Phenotypes
Current Medicinal Chemistry EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets Dendrimers in Therapy for Breast and Colorectal Cancer
Current Medicinal Chemistry The Clinical Genetics of Psoriasis
Current Genomics ADAM19/Adamalysin 19 Structure, Function, and Role as a Putative Target in Tumors and Inflammatory Diseases
Current Pharmaceutical Design Targeting Drug-Resistant Prostate Cancer with Dual PI3K/mTOR Inhibition
Current Medicinal Chemistry Management of Inflammatory Bowel Disease Patients with a Cancer History
Current Drug Targets